1. Introduction {#section0005}
===============

Human Bocavirus (HBoV) was first described by [@bib2] (Karolinska University Hospital, Stockholm) in 2005. The virus was identified in retrospectively analyzed clinical specimen from infants and children with respiratory tract infections (RTI). HBoV seems to be a worldwide distributed pathogen and has frequently been associated with respiratory tract infections among infants and young children. HBoV-positive patients also presented with symptoms of gastrointestinal disease ([@bib5], [@bib15]). HBoV DNA has recently been detected in stool samples of patients unrelated to respiratory infection ([@bib36]) raising questions about different possible modes of transmission.

Unlike patients with RSV-infection ([@bib25], [@bib31]), and similar to those with HMPV-associated respiratory tract infection ([@bib39]), children older than 6 months seem to be most at risk ([@bib15], [@bib23], [@bib38]). To this point there have only been few reports of infection in adult populations ([@bib6], [@bib23], [@bib32]). Detection of HBoV is only possible with RT-PCR ([@bib2]). Modified real time RT-PCR protocols have been recently published ([@bib16], [@bib20], [@bib21], [@bib27]) and detected 10^1^--10^10^  copies/mL in respiratory secretions of symptomatic patients. Hitherto, no animal model and no method for virus culture are available.

As Koch\'s revised postulates are not yet fulfilled for HBoV well designed clinical studies should investigate the association between the virus and respiratory and possible gastrointestinal manifestation ([@bib5], [@bib15]). However, statistical significant association between HBoV detection and previously unexplained disease ([@bib1], [@bib2]) and a significantly higher frequency of HBoV DNA detection in symptomatic than in asymptomatic individuals ([@bib1], [@bib2], [@bib15]) support the idea of a possible association of virus and clinical symptoms. Co-infection with other viral pathogens is a frequently confirmed feature in HBoV infection raising the question of causality ([@bib1], [@bib14], [@bib33]). At the Children\'s Hospital, University of Bonn, viral RTIs are prospectively investigated in a multicenter surveillance study since 1998 ([@bib31]). This report discusses the prospectively documented viral RTIs in hospitalized pediatric patients in the 2005--2006 winter season and focuses on the HBoV infections detected. To put our results into perspective, we analyzed 17 publications ([@bib2], [@bib5], [@bib6], [@bib7], [@bib10], [@bib11], [@bib14], [@bib15], [@bib16], [@bib20], [@bib21], [@bib22], [@bib23], [@bib26], [@bib27], [@bib32], [@bib33], [@bib38]) dealing with HBoV-infection.

2. Methods {#section0010}
==========

2.1. The clinical database-VIRTI Ped {#section0015}
------------------------------------

In November 1999 a specific software tool developed at our institution for the targeted surveillance of hospitalized RSV-infected pediatric patients was made available for data entry. Inclusion criteria and details of the surveillance protocol have been published recently ([@bib29], [@bib31]). In 2004, the database was modified and reopened to clinical data entry considering other pathogens which cause viral respiratory tract infections (VIRTI Ped database) ([@bib29], [@bib30], [@bib39]). For the purpose of this prospective analysis, all pediatric inpatients (hospitalized from November 01, 2005 to May 31, 2006) with virologically confirmed RSV, HMPV, HCoV and HBoV infection were included irrespective of age (\<18 years), underlying disease, comorbidity and whether the infection had been acquired in the hospital or at home. A lower respiratory tract infection was only documented as 'pneumonia' only if a chest radiograph confirmed the clinical diagnosis ([@bib8]). The study protocol of the VIRTI Ped Study was approved by the ethics committee of the University of Bonn. Before enrolment and data entry into the database, informed consent was obtained from parents or the patients' legal guardians.

3. Virological methods {#section0020}
======================

Nasopharyngeal specimen from patients suffering from respiratory illness were tested as previously described for the following viruses: RT-PCR for human coronaviruses (NL63, SARS, HKU1, OC43, 229E) as described below, RT-PCR for human metapneumovirus ([@bib28], [@bib35], [@bib39]), RT-PCR and NOW^®^ RSV ELISA (Inverness Medical, Cologne, Germany) for respiratory syncytial virus ([@bib31]), human influenza viruses A and B and NOW^®^ Influenza A/B ELISA (Inverness Medical, Cologne, Germany), and Human Bocavirus ([@bib2], [@bib19], [@bib30]). Except for human coronaviruses all methods were described in detail previously ([@bib2], [@bib19], [@bib28], [@bib31], [@bib35], [@bib39]).

For the amplification of HCoV-specific sequences RNA was extracted from nasopharyngeal aspirates with the QIAamp MinElute Virus Spin Kit (QIAGEN, Hilden, Germany) and subjected to a single-round RT-PCR (QIAGEN, Hilden, Germany) using a set of primers designed on the basis of comparison of *pol* ORF1b sequences of known human coronaviruses ([@bib19]). RT was carried out for 30 min at 42 °C followed by a PCR with one initial step of denaturation (95 °C for 5 min), 35 cycles of amplification (95 °C for 30 s, 50 °C for 30 s, 72 °C for 30 s) and a final elongation step (72 °C for 5 min). The primers used for the pan-coronavirus PCR were sv387as (5′-TCA CAY TTW GGA TAR TCC CA), sv388s (5′-ACT CAR ATR AAT CTT AAR TAY GC), and sv389s (5′-ACT CAA ATR AAT TTR AAR TAY GC) at final concentrations of 0.6 μM each. PCR-amplicons with a length of 251 basepairs were electrophoresed on an agarose gel and visualized by ethidium bromide staining. All positive PCR results, especially those that were positive for Human Bocavirus, were confirmed by sequencing.

Other common respiratory viruses such as human parainfluenza virus, human rhinoviruses or adenovirus were not included in the screening panel.

3.1. Sequencing of bocavirus PCR-amplificates {#section0025}
---------------------------------------------

Amplicons were purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany) and subjected to sequencing in both directions (BigDye Terminator DNA sequencing kit v3.1, Applied Biosystems, Darmstadt, Germany) as previously described ([@bib28]). BlastN (<http://www.ncbi.nlm.nih.gov/BLAST>) was used for comparison of the obtained sequences to nucleotide sequence databases.

4. Results {#section0030}
==========

From November 01, 2005 to May 31, 2006, 389 nasopharyngeal aspirates (NPA) from hospitalized pediatric patients with respiratory tract infection were investigated. Specimens from 2.8% (*n*  = 11) of all patients were positive for HBoV. RSV, HMPV, HCoV, Influenza B viruses were detected in 13.9% (*n*  = 54), 5.1% (*n*  = 20), 2.6% (*n*  = 10), and 1.8% (*n*  = 7), respectively. There was no influenzavirus A detected.

Taken together, in 23.4% of all investigated children, at least one of the viral pathogens included into the diagnostic panel could be detected. Most patients with HBoV infection were found in December 2005 ([Fig. 1](#fig1){ref-type="fig"} ). The proportion of the HBoV-positive specimens referring to all investigated specimens varied between 0.0% and 5.7% in the corresponding month of surveillance ([Fig. 2](#fig2){ref-type="fig"} ). The median age of the HBoV-positive patients was 9.0 months (range, 3--17 months), eight (73%) were male. The median duration of symptoms before the admission to the hospital was 4 days (range 1--23 days), the median duration of hospitalization was 5 days (range 2--15 days). One patient had a preexisting comorbidity (premature birth, birth weight 980 g). The clinical diagnosis was acute wheezing (bronchitis) in four patients, pneumonia in six patients (55%) and croup syndrome in one patient. In eight (73%) HBoV-positive patients, the attending physicians ordered a chest radiograph, which yielded pathologic findings in seven patients (one peribronchitis, four bronchopneumonias, two lobar pneumonias). In five of six patients with radiologically confirmed pneumonia, HBoV was the only pathogen detected. While no patient had to be mechanically ventilated, 73% needed oxygen supplementation. The median leukocyte count at diagnosis was 11.3 × 10^9^  L^−1^ (range: (6.7--16.7) × 10^9^  L^−1^); the median C-reactive protein was 12.5 mg/L (normal \< 0.3mg/L; range: \< 0.3--114 mg/L). The patients received treatment with betamimetics (inhalative; 10/11; 91%), systemic steroids (6/11; 55%) and antimicrobial chemotherapy (9/11; 82%); it has to be considered, that only in those patients with RSV-coinfection, the attending physicians were aware of a viral pathogen at the time of the clinical event. Beside one patient, in whom HBoV was detected at two consecutive days in two respiratory specimens, no follow up investigations were performed. In 7 of 11 HBoV-positive patients no other pathogen was detected, in 4 (36.4%) at least one other viral pathogen was found (plus RSV *n*  = 3; 27.3%; Norovirus *n*  = 1; 9.1%).Fig. 1Distribution of the positive specimens (absolute numbers) of the investigated viral respiratory pathogens in the corresponding months of prospective surveillance.Fig. 2Monthly distribution of the proportion of HBoV-positive specimens (in %) related to all tested nasopharyngeal aspirates.

5. Discussion {#section0035}
=============

This report represents the first prospective investigation of hospitalized pediatric patients with HBoV infection. Although the proportion of HBoV-positive specimens (2.8%) in our study was relatively low (range in the literature 1.5% ([@bib6]) to 18.3% ([@bib14])), illness severity was remarkable with radiological confirmed pneumonia and need for oxygen supplementation in the majority of the patients. Another recently published prospective study detected HBoV in five (4.5%) of 112 infants with RTI in a birth cohort study in Switzerland ([@bib26]); all these infants had mild disease and none was hospitalized. So, to define the definite role of HBoV as a respiratory pathogen, prospective population-based multicentre studies will have to be performed.

5.1. Seasonality {#section0040}
----------------

Most authors observed a higher prevalence of HBoV-infection in the cold winter and spring months ([@bib2], [@bib26], [@bib33]). Choi et al. (Corea 2000--2005) ([@bib7]) reported a relatively high occurrence of HBoV in late spring and early summer and [@bib6] from Canada detected HBoV throughout the year with no apparent seasonal prevalence.

Our data was collected during the months November 2005 and May 2006 and therefore, cannot contribute to an evaluation of the incidence of HBoV during the warm months of summer and early fall. Nevertheless, it showed a steady incidence during the cold months of fall and winter ([Fig. 2](#fig2){ref-type="fig"}) in accordance with most authors ([@bib2], [@bib5], [@bib15]).

5.2. Prevalence {#section0045}
---------------

The prevalence of HBoV-infection (more precisely defined: the detection of HBoV-genome in respiratory secretions of symptomatic patients) among hospitalized children with respiratory tract infection in the analyzed studies ranged between 1.5% ([@bib6]) and 18.3% ([@bib14]). The majority of children with HBoV-infection was younger than 24 months ([@bib2], [@bib32], [@bib33]). Two recently published studies included control groups of asymptomatic children ([@bib15], [@bib23]). Kesebir and co-workers isolated HBoV DNA in 22 of 425 NPA specimens from symptomatic children while in none of the specimens from 96 asymptomatic children HBoV DNA could be detected. Only one of the 21 HBoV-positive patients in the Scottish study was an asymptomatic child ([@bib23]).

5.3. Symptoms and clinical diagnoses {#section0050}
------------------------------------

Clinical symptoms most frequently associated with Human Bocavirus infection include cough, rhinorrhea and fever up to 39.5 °C ([@bib27]). Gastrointestinal symptoms were described in up to 25% of all patients ([@bib5], [@bib15]).

Two of the HBoV DNA positive individuals (18%) presented with diarrhea. In one of the two patients norovirus was detected in a stool sample, whereas the other patient showed no other pathogen in stool specimens. However, our study was not designed to evaluate gastrointestinal disease.

Members of the parvovirus family described in cattle cause gastrointestinal symptoms. Considering the stability of the human parvovirus B19, long-term persistence of HBoV in the inanimate environment may foster a fecal-oral route of transmission via contaminated fomites. Further studies should consider testing stool samples for Human Bocavirus to confirm gastrointestinal manifestation. The most common clinical diagnoses of HBoV-positive patients included upper respiratory tract infection, bronchitis, bronchiolitis, pneumonia and exacerbation of asthma bronchiale.

This spectrum of diagnoses is in accordance with other viral respiratory tract infections. Similar to the situation in RSV- and in HMPV-infection ([@bib40]) there is a lack of international consensus about the definition of certain diseases which are important in this clinical context ([@bib3], [@bib34]).

Two studies provided differing definitions ([@bib5], [@bib7]) whereas the 15 remaining publications do not describe their criteria. The percentage of 'bronchiolitis' within the diagnostic spectrum ranged between 3.2% ([@bib38]) and 46% ([@bib10], [@bib11]). Only 6 out of 17 publications ([@bib2], [@bib5], [@bib15], [@bib16], [@bib22], [@bib27]) stipulated radiological confirmation of any 'pneumonia'. Similar to RSV ([@bib37]) or HMPV ([@bib39]), there are no distinct clinical signs in HBoV-infected patients which allow an etiological diagnosis on clinical grounds alone.

5.4. Laboratory findings {#section0055}
------------------------

[@bib5] reported a median leukocyte count of 13.3 × 10^9^  L^−1^; [@bib22] found a median leukocyte count of 13.1 × 10^9^  L^−1^ and a median CRP of 0.6 mg/L (\< 0.2--4.48) in HBoV-infected subjects. This confirms our findings, that elevated leukocyte and CRP-values may be found in HBoV-infected children.

5.5. Radiological findings {#section0060}
--------------------------

The high percentage of pathological findings on chest radiographs in our study is in accordance with the results of other clinical research groups, which ranged from 43% ([@bib2]) to 83% ([@bib10], [@bib11], [@bib16]). Allander and co-workers reported interstitial bilateral infiltrates in six of seven performed chest-X-rays. Obviously, HBoV does not only cause central pneumonia ([Fig. 1](#fig1){ref-type="fig"}) but also interstitial and lobar pneumonia with or without pleural effusion ([@bib27]). Neither clinical symptoms nor laboratory parameters nor radiological findings are sufficient to make a clear distinction between bacterial and viral cause of pneumonia in these patients ([@bib17], [@bib18], [@bib24]).

5.6. Coinfection {#section0065}
----------------

The results of our study show a coinfection rate of 36%. Such high percentage was also found in the majority of the analyzed studies which report coinfection rates of 18% ([@bib2]) to 72% ([@bib14]) with RSV being the most prevalent copathogen in most studies ([@bib16]). [@bib23] detected a significantly higher rate of coinfections in HBoV-positive patients (43% \[23/53\] vs. 17% \[47/271\] positive for another viral pathogen; *P*  \< 0.001). Differences in sensitivity of screening methods and the diagnostic panel for the detection of additional respiratory pathogens strongly affect coinfection rates. Our study\'s respiratory virus panel did not include adenovirus, human parainfluenza virus and human rhinovirus which might have contributed to an even higher rate of coinfection.

5.7. Incubation period and nosocomial infection {#section0070}
-----------------------------------------------

Since the incubation period of HBoV-infection is unknown it is not possible to comment on the incidence rate of nosocomial infections. So far there have been neither studies on the tenacity of the virus nor the effect of commonly used disinfectant soap and solutions ([@bib13]). Parvovirus B19 shows high tenacity and great resistance to commonly used disinfectants ([@bib9]). Due to the close relationship within the family of the Parvoviridae it is possible that HBoV shows similar characteristics. Kesebir and co-workers reported three patients (14%) with nosocomial HBoV-infection (*n*  = 22). The infected infants (1, 4 and 6 months of age) had been hospitalized since birth. Sequencing of two isolates showed identical nucleotide sequences. [@bib16] described three additional HBoV DNA positive patients, who developed respiratory symptoms after hospital treatment for other diseases for at least 4 weeks. [@bib15] reported three patients (14%) with nosocomial HBoV infection (*n*  = 22). Vertical transmission has not been ruled out as the authors did not acquire NPAs from the parents. None of the patients described in our study was suspected to have a nosocomially acquired HBoV infection.

5.8. Treatment with antibiotics {#section0075}
-------------------------------

In our centre 82% of HBoV-positive patients received antibacterial chemotherapy. Before HBoV was known, for the responsible physicians, children with HBoV-infection are mostly "RSV-negative patients with pneumonia".

The uncertain etiology of the clinical illness of respiratory infections may explain the excessive application of antibiotics.

5.9. HBoV and asthma bronchiale {#section0080}
-------------------------------

Viral infection of the respiratory tract has frequently been associated with recurrent airway obstruction ('wheezing') among infants and asthma exacerbation among older children. In our patients 4 out of 11 presented with wheezing as the leading symptom of their respiratory infection. All recently published clinical studies on HBoV report asthma exacerbation as a clinical symptom in up to 27% of the HBoV-positive patients ([@bib5], [@bib10], [@bib11]). Half of the patients in the study by [@bib2] presented asthma bronchiale as an underlying disease. Recently, [@bib1] detected HBoV in 49 of 259 (19%) children (median age 1.6 years) hospitalized with acute wheezing. A large proportion of the cases were mixed infections with other viruses, but HBoV was the only virus detected in 12 children (5%). High viral loads of HBoV were noted mainly in the absence of other viral agents, suggesting a causative role for acute wheezing. In addition, infections that had uncertain clinical relevance and low viral loads were prevalent. HBoV DNA was frequently detected in serum specimens obtained from patients with acute wheezing, suggesting systemic infection. These recent results suggest a model for HBoV infection in which high viral loads are potentially associated with respiratory symptoms and low viral loads indicate asymptomatic shedding. Therefore, quantitative polymerase chain reaction analysis may be important for additional studies of HBoV ([@bib1], [@bib4]).

5.10. HBoV and immunosuppression {#section0085}
--------------------------------

Several clinical research groups reported HBoV-positive immunosuppressed/ immunodeficient patients in their studies ([@bib5], [@bib23], [@bib33]). [@bib5] presented two pediatric patients with HBoV-infection after organ transplantation. [@bib33] reported HBoV-infection in eight HIV-infected pediatric patients and Manning and co-workers included two infected non-specified immunosuppressed adult patients in their study ([@bib5], [@bib23], [@bib33]). There were no immunocompromised individuals among the HBoV DNA positive patients treated at our center during the winter season 2005/2006.

Our group has recently published the clinical case of a severe HBoV-infection of a 28-year-old female patient with malignant B-cell lymphoma ([@bib19]). On admission the patient showed pancytopenia, high fever and clinical and radiological signs of pneumonia (reticulo-nodular infiltrates in the CT-scan of the thorax). Despite the application of antibiotics, antifungal agents and ganciclovir the patient presented persistent fever for 14 more days. HBoV was retrospectively detected as the sole pathogen in the nasopharyngeal aspirate of this high-risk patient. The patient was discharged after 41 days of hospitalization.

5.11. Open questions for further studies {#section0090}
----------------------------------------

As long as we do have only a limited number of studies comparing detection rates in symptomatic and asymptomatic people ([@bib12]), and neither an animal model nor a reliable cell culture method ([@bib4]), it remains difficult to confirm Koch\'s postulates and prove the causative role of HBoV as a real pathogen.How high is the rate of hospitalization in infected outpatients?Fecal excretion of HBoV as shown by [@bib36] adds new concern about the transmission of HBoV. Is HBoV transmitted via fecal contamination in addition to respiratory secretions?Human Bocavirus is prevalent among children with acute wheezing and can cause systemic infection ([@bib1]), raising the question whether there is a risk of parenteral transmission via blood products or blood contamination.Also tenacity of HBoV has not been determined yet and its susceptibility to hospital grade disinfectants will have to be investigated.Studies from the United States and Germany reported nosocomial infections ([@bib15]). However, due to the limited number of investigated cases the true impact of HBoV as nosocomial infection remains uncertain. Its investigation requires additional prospective studies.Co-infection is a frequent finding in HBoV DNA positive patients. It remains to be determined whether HBoV plays a role modifying the clinical presentation of other viral respiratory tract infections (RSV, HMPV).To this point authors have collected very little data to evaluate the probability of bacterial superinfection in HBoV infection.Having been subject to several studies concerned with pediatric populations HBoVs role as a pathogen in adult populations has still to be investigated. Is HBoV a clinically relevant pathogen among the elderly (COPD, patients \>60 years of age) and among patients with underlying diseases and predisposing risk factors (immunodeficiency, chronic lung diseases, prematurity)?

Due to the retrospective manner of data collection of most of the performed studies no sufficient evaluation of the outcome of therapeutic interventions could be made to this point. Which therapeutic interventions are of confirmed benefit in children with severe HBoV infection? Prospective multicenter population based studies and much additional work in the virological laboratories will be necessary to clear up these points.
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